



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/599,980

04/03/2007

Roland Reiner

Q99617

7700

23373 7590 11/14/2008  
SUGHRUE MION, PLLC  
2100 PENNSYLVANIA AVENUE, N.W.  
SUITE 800  
WASHINGTON, DC 20037

EXAMINER

KRISHNAN, GANAPATHY

ART UNIT

PAPER NUMBER

1623

MAIL DATE

DELIVERY MODE

11/14/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/599,980	<b>Applicant(s)</b> REINER ET AL.	
	<b>Examiner</b> Ganapathy Krishnan	<b>Art Unit</b> 1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 13 August 2008.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 23 and 27-49 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 23 and 27-49 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

The amendment filed 8/13/2008 has been received, entered and carefully considered.

The following information provided in the amendment affects the instant application:

1. Claims 1-22 and 24-26 have been canceled.
2. New Claim 48 has been added.
3. Claims 23, 27-28, 33, 36 and 38-41 have been amended.
4. Remarks drawn to rejections under 35 USC 112, second paragraph, 102 and 103.

Claims 23 and 27-48 are pending in the case.

The rejection of Claims 38 and 41 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention has been overcome by amendments.

The rejection of Claims 23-25, 27, 38, 42-44 under 35 U.S.C. 102(b) as being anticipated by Marler et al (Plast. Reconstr. Surg., 2000, 105, 2049-2058; document cited in International Search Report of 10/16/2006) and,

The rejection of Claims 23-25, 29, 31 and 38 under 35 U.S.C. 102(b) as being anticipated by Bent et al (Neurourology and Urodynamics, 2001, 20, 157-165; document cited in International Search Report of 10/16/2006) have both been overcome in view of amendments to the claims and applicants' arguments. Applicants have amended instant claim 23 to recite a molecular weight range of the alginate. Both Marler et al and Bent et al do not teach the molecular weight range for the alginate as instantly claimed.

Art Unit: 1623

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The rejection of Claims 23 and 27-48 under 35 U.S.C. 103(a) as being unpatentable over Marler et al (Plast. Reconstr. Surg., 2000, 105, 2049-2058; document cited in International Search Report of 10/16/2006), in view of Bent et al (Neurourology and Urodynamics, 2001, 20, 157-165; document cited in International Search Report of 10/16/2006), Agerup (US 5,633,001;

Art Unit: 1623

document cited in International Search Report of 10/16/2006), Vanderhoff et al (WO 96/39464; document cited in International Search Report of 10/16/2006), The Merck Index (12<sup>th</sup> Edition, 1996, page 758, entry # 4465) and Hawley's Chemical Dictionary (1997, page 1092) is being maintained for reasons of record.

Marler et al teach tissue augmentation (increasing shape and volume) via subcutaneous injection of a composition comprising an alginate, into a rat (page 2049 Abstract, first, second and last paragraphs; page 2050, right column, first full paragraph). The composition comprised of 1% medium viscosity alginate and a medium viscosity alginate covalently bonded to RGD-a cell adhesion peptide. The alginates were used in cell culture medium to provide nutrients and phosphate buffered saline (page 2050, right col., last paragraph). The alginate was reconstituted as a 2% solution and gelled via crosslinking with calcium ions (page 2051, left col., first full paragraph). The alginate solutions with or without the cells were allowed to gel in vivo, after injection of a mixture of alginate, cell and calcium ions (page 2051, right column, first paragraph).

Bent et al teach the treatment of incontinence by injection of alginate solution crosslinked (gelled) with calcium ions and containing chondrocytes, into the sphincter muscle (page 157, abstract through page 158, middle).

However, Marler et al and Bent et al do not teach the molecular weight of the alginate and the use of microparticles of alginate crosslinked with barium even though the use of alginate microparticles are disclosed, and injection into muscle tissue.

Agerup, drawn to method of tissue augmentation, teaches enlargement of tissue (same as increasing volume) like esophagus, various sphincters, urether and rectum via injection of a

Art Unit: 1623

composition comprising a carrier gel, which could be alginate (0.05-50%) in combination with tissue augmenting substance, which could be a carbohydrate polymer (col. 1, lines 5-16; col. 2, lines 45-59). The composition can additionally contain therapeutically active substances like growth factors, hormones, vaccines, cytokines, antivirals, bactericidal compounds and other pharmacologically active compounds (col. 2, line 65 through col. 3, line 8). Example 2 teaches the use of alginate as a carrier gel, which is made harder (i.e, gelled by crosslinking) with calcium ions (col. 3, lines 54-61). Even though Agerup uses alginate as a carrier, one of skill in the art will recognize, based on the teaching of Marler that alginate itself could be used for augmentation either alone or in combination with other agents.

Vanderhoff et al teach polymer particles of about 150 micrometers for use in soft tissue augmentation (page 4, line 20 through page 5, line 4). The injectable particles can also contain encapsulated drugs and medications (page 5, lines 5-9; lines 25-31; page 7, lines 6-35). The water soluble polymers can be polysaccharides (page 8, lines 32-34). One of the desirable polymers is sodium alginate, since it is biocompatible, biodegradable, and non immunogenic and in the form of microspheres is a good candidate as carrier of drugs (page 9, lines 7-20). Several types of crosslinking agents can also be used depending upon the polymer used and can be readily determined by one of skill in the art (page 9, lines 21-35). For crosslinking of the microparticles, pH can be adjusted to adjust the rate of crosslinking (page 10, lines 20-21). Even though Vanderhoff's teaching is drawn to a process for producing microparticles, he suggests the use of such particles also for tissue augmentation. One of skill in the art will use such microparticles of alginate for tissue augmentation as taught by Marler, Bent and Agerup.

Art Unit: 1623

The Merck Index and Hawley's both teach that gluconolactone and EDTA are complexing (sequestering) agents.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use alginates, crosslinked and uncrosslinked, in the form of microspheres, for increasing the volume of tissue in a subject, as instantly claimed since the use of such is taught using analogous alginates for the same purpose.

One of skill in the art would be motivated to use alginates in the method as instantly claimed since Marler teaches that the use of alginates offers additional advantages like chemical modification to induce desirable properties, is readily available and has been approved by FDA for use in human patients (Marler, page 2054, right column, first and second paragraphs). According to Vanderhoff, one of the desirable polymers is sodium alginate, since it is biocompatible, biodegradable, and non immunogenic and in the form of microspheres is a good candidate as carrier of drugs (page 9, lines 7-20). With so many advantages, one of skill in the art would prefer to use alginate over other polymers suggest in the prior art.

One of skill in the art would also prefer to use EDTA or gluconolactone since both are taught to be sequestering agents. Their ability to form covalent bonds would be an advantage in addition to ionic bonds formed by the metal ions during crosslinking (Vanderhoff page 9, line 35 through page 10 line 1). The use of citrate is also logical since it is a component of the well known citrate buffer used for adjusting pH. In line with the teaching of Vanderhoff regarding the adjustment of pH for adjusting the rate of crosslinking, the use of the biocompatible citrate is preferable (Vanderhoff page 10, lines 20-21). It is well within the skill level of the artisan to

Art Unit: 1623

adjust the percentages of the agents, the size of the microparticle and the molecular weight of the alginate in order to obtain maximum beneficial effects.

### ***Response to Applicants' Arguments***

Applicants have traversed the 103(a) rejection of record arguing that:

1. Marler and Bent do not teach or suggest the use of microparticles and high molecular weight alginate.
2. Vanderhoff relies on covalently crosslinked alginate material and not on ionically crosslinked material. The technology of Vanderhoff cannot possibly be based on ionic linkers since molecular weight of the alginate is much lower than instantly claimed. Vanderhoff's process leads to further issues like impurities and toxicity.
3. Agerup is completely different from the subject matter currently claimed since it uses dextranomic microbeads for tissue augmentation and also does not teach the use of high molecular weight alginate.

Applicants' arguments have been considered but are not found to be persuasive.

Marler and Bent may not have taught or suggested the use of microparticles and high molecular weight alginate. But Vanderhoff teaches crosslinked microspheres of sodium alginate and their use in tissue augmentation. Irrespective of the molecular weight the alginate can be crosslinked with ionic crosslinkers. Vanderhoff also teaches the need for non-cytotoxic, non-carcinogenic, non-inflammatory particles to make solutions for use in soft tissue augmentation (page 3, lines 20-25). One of skill in the art also knows that ions like calcium, sodium and barium are biocompatible and are used as nutrients. Hence, based on the suggestion by



Art Unit: 1623

Vanderhoff regarding the need for non-cytotoxic particles one of skill in the art would prefer to use ionic crosslinkers instead of covalent crosslinkers. The process of Vanderhoff is not relevant. Impurities can be removed by purification. Agerup exemplifies a similar invention with dextranomer. His invention is still relevant to the instant invention since it deals with ionically crosslinked polymeric materials for tissue augmentation. Even though the prior art of record does not suggest a molecular weight range for the alginate one of skill in the art would optimize the molecular weight of the alginate in order to obtain maximum beneficial effects. Such optimization is routine in the art.

### ***Conclusion***

Claims 23 and 27-48 are rejected

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1623

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathy Krishnan whose telephone number is 571-272-0654.

The examiner can normally be reached on 8.30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ganapathy Krishnan/

Examiner, Art Unit 1623

/Shaojia Anna Jiang/

Supervisory Patent Examiner, Art Unit 1623